retatrutide name brand Retatrutide, an experimental weight-loss drug, has not been approved by the FDA. But, doctors and nurse practitioners in clinics across the country are prescribing it anyway, a CBS News investigation found. @adamyamaguchi Retatrutide vs. semaglutide: A head-to-head

GLP-1 Market Report Scope : Segmentation of GLP-1 Market - GLP-1 Market by Type of Molecule - Biologic Peptide GLP-1 Agonists Small-Molecule Non-Peptide GLP-1 Agonists GLP-1 Market by Active Compound Used - Semaglutide Tirzepatide Dulaglutide Liraglutide Lixisenatide Exenatide Orforglipron Retatrutide Survodutide Other Active Compounds GLP-1 Market by Type of GLP-1 Agonist Drugs - Long-acting GLP-1 Agonist Short-acting GLP-1 Agonist GLP-1 Market by Type of Agonist - Single agonist Dual agonist Tri-agonist GLP-1 Market by Route of Administration- Oral Parenteral GLP-1 Market by Target Indication- Alzheimers Disease Non-Alcoholic Steatohepatitis Obesity Sleep Apnea Type 2 Diabetes GLP-1 Market By Dosing Frequency- Daily Weekly Monthly or Extended-Interval GLP-1 Market By Delivery System- Disposable Pre-filled Pen Auto-Injector Pre-filled Syringe Oral Tablet / Capsule GLP-1 Market By Payer- Retail Pharmacy Commercial Insurance Retail Pharmacy Government (Medicare / Medicaid) Specialty / Mail-Order Pharmacy Self-Pay GLP-1 Market by Region- North America- The US Canada Mexico Europe- Germany The UK France Italy Spain Rest of Europe Asia-Pacific- China Japan India South Korea Southeast Asia Rest of Asia Pacific Latin America- Brazil Argentina Rest of Latin America Middle East & Africa- GCC Countries South Africa Rest of the Middle East and Africa Research Design and Approach This study employed a multi-step, mixed-method research approach that integrates: Secondary research Primary research Data triangulation Hybrid top-down and bottom-up modelling Forecasting and scenario analysis This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market

Note that for purposes of this article, firms were included in the OTC product category if the warning letter mentioned an OTC product

Exendin-4 protects the hearts of rats from ischaemia/reperfusion injury by boosting antioxidant levels and inhibition of JNK/p(66) Shc/NADPH axis

Ongoing research is exploring its potential benefits in preventing dementia, muscle atrophy, and kidney disease

Journal reference: Wang, M